Semaglutide's Long-Term Impact on Appetite and Eating Behavior in Obesity

Obesity is a complex chronic disease characterized by excessive body fat, often leading to significant health complications. While semaglutide (marketed as Wegovy for weight loss) has demonstrated efficacy in promoting weight reduction, the specific mechanisms by which it influences appetite and eating behavior over extended periods are not fully understood. This study aims to comprehensively evaluate the long-term effects of semaglutide on hunger, fullness, food liking, and psychosocial status in individuals with obesity.

As of the current information, this study is completed but the results have not yet been published. Therefore, specific data on appetite reduction, changes in eating behavior, or psychosocial status improvements are not available. The trial is designed to measure quantitative changes in subjective hunger and fullness ratings, objective food intake patterns, and self-reported food liking. It will also assess psychosocial outcomes related to eating. The primary objective of this trial is to determine the long-term efficacy of semaglutide 2.4 mg in modulating appetite, eating behavior, and psychosocial well-being over 60 weeks in individuals with obesity. Researchers anticipate that semaglutide will lead to a significant decrease in hunger and an increase in satiety, potentially resulting in reduced caloric intake and improved weight management compared to the placebo group.